New Outpatient COVID-19 Treatments - Guideline Knowledge CheckAndrea Eberly, MD, MS, FAAEM examines newly updated COVID-19 recommendations from the NIH and IDSA addressing the omicron variant and two newly authorized oral antiviral treatments for ambulatory patients with COVID-19.
In January / February 2022, both the National Institutes of Health (NIH) and Infectious Diseases Society of America (IDSA) updated their COVID-19 recommendations to address the omicron variant and include two newly authorized oral antiviral treatments for ambulatory patients with COVID-19.
What do these guidelines state about the indications / contraindications of these two new oral drugs (molnupiravir and ritonavir/nirmatrelvir [plaxovid]) and the two previously authorized intravenous drugs (remdesivir and sotrovimab) that are now recommended for ambulatory patients with COVID-19 that is likely due to omicron?
Try this case and test your knowledge of the new guidelines for these outpatient COVID-19 treatments.
In a busy emergency department several patients are presenting with fever and mild to moderate COVID-19 symptoms (fatigue and various degrees of respiratory symptoms).
Four of these patients are testing positive for SARS-CoV-2 during a time when omicron is the dominant variant.
They all have various risk factors for severe COVID-19 disease and meet indications for COVID-19 treatment as an outpatient.
Which patient is correctly matched to an outpatient COVID-19 treatment option?
See the Answer:
Dr. Andrea Eberly is one of the seasoned medical experts that contribute to Med-Challenger Medical Education products for medical board certification exam preparation, maintenance of medical certification, and continuing medical education requirements.
Med-Challenger EM PRO BundleEverything in Emergency Medicine
$3672 in value. You save over 44%.
Ideal use of your CME Budget!
EM PRO VALUE BUNDLE - Everything emergency medicine physicians need for knowledge excellence, ABEM exam review, annual MOC requirements, including all MyEMCert modules, annual LLSAs and specialty CME credits, over their entire career - for one great value price.
Call 1-800-676-0822 or email@example.com
If you already own any of the titles in EM PRO, contact us for special discounts and upgrade pricing.
EM PRO bundle includes:
CME Credit Totals:
- 650+ AMA PRA Category 1 CME Credits
- 60 ACEP-approved CME Credits
- 53 AAP Category 1 CME Credits
- 53 ABP MOC Part II CME Credits
Kristy Johnson, MD
EM PRO is the best medical education purchase I've ever made. Pays off every year.
More from Med-ChallengerThe Leader in Online Board Review, CME Courses, and Medical Education
Did you like this?
Get more free medical Q&A and informative CME articles.
Subscribe to the Medical Education Blog
More from Med-Challenger's Medical Education Blog
Pediatric Advanced Airway, Free CME Quiz – Earn AMA and ANCC Credits FreeSeptember 27, 2022
PEMQBook Board Review Course 2023 – 2023 Pediatric Emergency Medicine Live Review Course, Dates, and RegistrationSeptember 20, 2022
Opioid Toxicity – Heroin Abuser with Sudden Shortness of Breath – Clinical Patient Case of the WeekSeptember 20, 2022
Board Review & CME Offers
Med-Challenger provides online medical education, top-rated board review courses, annual MOC and CME credit solutions for physicians, nurses, PAs and students. Take advantage of our current offers.
PROCareer Value Bundles
in your specialty.
Useful every year.
Ideal use your CME budget.